Edition:
United States

Bayer AG (BAYGn.DE)

BAYGn.DE on Xetra

52.53EUR
11:35am EDT
Change (% chg)

€-0.32 (-0.61%)
Prev Close
€52.85
Open
€52.79
Day's High
€52.98
Day's Low
€52.21
Volume
2,295,087
Avg. Vol
3,502,858
52-wk High
€99.90
52-wk Low
€52.02

About

Bayer AG is a life science company. The Company's segments are Pharmaceuticals, Consumer Health, Crop Science and Animal Health. The Pharmaceuticals segment focuses on researching, developing and marketing prescription products and specialty therapeutics especially in the areas of cardiology, oncology, gynecology, hematology and... (more)

Overall

Beta: 0.98
Market Cap(Mil.): €96,918.28
Shares Outstanding(Mil.): 826.95
Dividend: 2.70
Yield (%): 2.30

Financials

  BAYGn.DE Industry Sector
P/E (TTM): 22.18 29.30 32.55
EPS (TTM): 5.29 -- --
ROI: 8.69 14.23 13.82
ROE: 16.39 15.46 15.24

Bayer to invest $5.6 billion in weedkiller research to help reputation

FRANKFURT Germany's Bayer sought to repair its reputation on Friday after damage caused by U.S. litigation over claims its glyphosate pesticide causes cancer, saying it would invest 5 billion euros ($5.6 billion) in weedkiller research.

Jun 14 2019

UPDATE 2-Bayer to invest $5.6 bln in weedkiller research to help reputation

* CEO seeks to improve image amid U.S. glyphosate lawsuits (Adds details on investment, developing countries, lobbyist)

Jun 14 2019

Bayer says to invest 5 bln euros in new weed killers

BERLIN, June 14 Bayer said it would invest 5 billion euros ($5.6 billion) in developing new weedkillers and reducing its environmental impact by 30% by 2030, as it seeks to address the fallout from U.S. class-action litigation over glyphosate.

Jun 14 2019

Bayer wins dismissal of 920 Mirena products liability lawsuits

A federal judge on Tuesday dismissed lawsuits by 920 women alleging they had developed a rare neurological condition after using Bayer AG's Mirena contraceptive device, saying they lacked evidence showing it can cause the disease.

Jun 11 2019

Bayer teams up with biotech firm Arvinas in deal worth up to $750 million

FRANKFURT German drugmaker Bayer has signed an alliance with Arvinas Inc to gain access to the U.S. biotech firm's experimental protein drugs and crop protection technology in a deal worth up to $750 million.

Jun 04 2019

Bayer teams up with biotech firm Arvinas in deal worth up to $750 mln

FRANKFURT, June 4 German drugmaker Bayer has signed an alliance with Arvinas Inc to gain access to the U.S. biotech firm's experimental protein drugs and crop protection technology in a deal worth up to $750 million.

Jun 04 2019

Australian gardener sues Bayer's Monsanto over cancer link

SYDNEY Lawyers of an Australian gardener on Tuesday said they had filed a lawsuit against Bayer AG agricultural chemicals unit Monsanto for severe harm caused by an ingredient used in its weed killer Roundup, the first such case in the country.

Jun 04 2019

Australian gardener sues Bayer's Monsanto over cancer link

SYDNEY, June 4 Lawyers of an Australian gardener on Tuesday said they had filed a lawsuit against Bayer AG agricultural chemicals unit Monsanto for severe harm caused by an ingredient used in its weed killer Roundup, the first such case in the country.

Jun 04 2019

UPDATE 1-Bayer to work with Foundation Medicine on cancer patient screening

* Genetic sequencing test seen as vital to secure market uptake

May 29 2019

Bayer to work with Foundation Medicine on selecting cancer patients

FRANKFURT Bayer struck a collaboration deal with Roche's Foundation Medicine Inc. to develop test kits for genetic sequencing of tumor cells to identify cancer patients that benefit from Bayer's Vitrakvi drug.

May 29 2019

Earnings vs. Estimates